NASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis $0.18 +0.00 (+1.73%) As of 03:23 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About KALA BIO Stock (NASDAQ:KALA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KALA BIO alerts:Sign Up Key Stats Today's Range$0.17▼$0.1950-Day Range$0.17▼$0.8252-Week Range$0.11▼$95.50Volume74,300 shsAverage Volume548,004 shsMarket Capitalization$3.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases. The company is centered on its mesenchymal stem cell secretome platform, which is designed to deliver multiple naturally occurring growth factors and proteins that may support tissue repair and reduce inflammation. KALA BIO’s lead investigational product candidate, KPI-012, is being developed for the treatment of persistent corneal epithelial defects, a condition in which the surface of the cornea does not heal properly. The company has evaluated KPI-012 in clinical studies and has pursued additional development opportunities in rare corneal diseases. The company was formerly known as Kala Pharmaceuticals and previously developed EYSUVIS, an ophthalmic corticosteroid approved in the United States for the short-term treatment of dry-eye disease symptoms. KALA BIO subsequently shifted its strategic focus toward rare diseases and regenerative ophthalmic therapies. Its activities are primarily centered on research and clinical development in the United States.AI Generated. May Contain Errors. Read More KALA BIO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreKALA MarketRank™: 0.689885241525 of 5 starsKALA BIO scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingKALA BIO has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageKALA BIO has only been the subject of 1 research reports in the past 90 days.Read more about KALA BIO's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about KALA BIO's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.85% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 0.67, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in KALA BIO has recently decreased by 60.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for KALA BIO this week, compared to 1 article on an average week.MarketBeat Follows2 people have added KALA BIO to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have not sold or bought any company stock.Percentage Held by Insiders2.24% of the stock of KALA BIO is held by insiders.Percentage Held by Institutions24.61% of the stock of KALA BIO is held by institutions.Read more about KALA BIO's insider trading history. Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KALA Stock News HeadlinesKala Bio Inc KALANovember 3 at 7:24 AM | morningstar.comMKALA Bio Signs LOI To Acquire Nationwide Telehealth Platform; Shares RiseSeptember 30, 2026 | rttnews.comRIP AI. It’s over.AI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the big tech names pouring billions into data centers. Walmart's $24 million satellite network, AMR's Sabre system, and Capital One's 36,114 pricing tests all prove the same thing: compute has always been business's biggest moat, and it's about to get cheaper than ever. Porter Stansberry says one overlooked, government-protected sector is positioned to absorb this near-free compute boom and could become the next Magnificent 7.November 4 at 1:00 AM | Porter & Company (Ad)Kala Bio, Inc. And Virotek Inc. Sign Letter Of Intent With U.S. DNA Testing Platform To Resell Virotek Inc.'s Suite Of Genetic Testing ProductsSeptember 25, 2026 | marketscreener.comMKala Bio, Inc. und Virotek Inc. unterzeichnen Absichtserklärung mit einer US-amerikanischen DNA-Testplattform zum Weiterverkauf der genetischen Testproduktpalette von Virotek Inc.September 25, 2026 | de.marketscreener.comDKala Bio And Virotek Sign LOI To Expand Genetic Testing DistributionSeptember 24, 2026 | rttnews.comKala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing ProductsSeptember 24, 2026 | globenewswire.comKALA BIO Adds Healthcare Operator Yenvy Truong to Advisory TeamSeptember 17, 2026 | globenewswire.comSee More Headlines KALA Stock Analysis - Frequently Asked Questions How have KALA shares performed this year? KALA BIO's stock was trading at $27.7950 at the start of the year. Since then, KALA shares have decreased by 99.4% and is now trading at $0.1770. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) announced its quarterly earnings results on Wednesday, August, 19th. The company reported ($21.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.00) by $15.32. When did KALA BIO's stock split? Shares of KALA BIO reverse split on Monday, May 11th 2026.The 1-50 reverse split was announced on Thursday, May 7th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), NIO (NIO), Exelixis (EXEL), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/19/2026Today11/04/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (13m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 KALA's financial health is in the Red zone, according to TradeSmith. KALA has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KALA CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees6Year Founded2009Profitability EPS (Trailing Twelve Months)($31.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-222.35% Return on Assets-70.23% Debt Debt-to-Equity RatioN/A Current Ratio6.88 Quick Ratio6.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.56 per share Price / Book0.01Miscellaneous Outstanding Shares19,340,000Free Float18,907,000Market Cap$3.40 million OptionableNot Optionable Beta-2.19 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:KALA) was last updated on 11/4/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc (OTCQB: VDTA) is building the layers beneath the AI boom - GPU hardware and financing, manag...Trading Wire | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALA Stock Alerts